Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

681
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
681
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

897
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
897
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

658
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
658
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

966
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
966
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

377
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
377
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.2K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same author

Is reduced right ventricular power after sotatercept beneficial?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Haemodynamic responses to sotatercept and parenteral prostacyclins in pulmonary arterial hypertension patients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.

Science translational medicine·2026
Same author

Diagnostic and management dilemmas in pulmonary hypertension.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Feb 18, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K

Acute decompensated pulmonary hypertension.

Laurent Savale1,2,3, Jason Weatherald4, Xavier Jaïs5,2,3

  • 1Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France laurent.savale@bct.aphp.fr.

European Respiratory Review : an Official Journal of the European Respiratory Society
|November 17, 2017
PubMed
Summary
This summary is machine-generated.

Acute right heart failure in pulmonary hypertension is a severe condition with poor prognosis. Management focuses on triggers, fluid optimization, and reducing right ventricular afterload, with extracorporeal support and transplantation offering hope for select patients.

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K

Related Experiment Videos

Last Updated: Feb 18, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Critical Care

Background:

  • Acute right heart failure (ARHF) in chronic precapillary pulmonary hypertension (PH) presents as a rapidly progressive syndrome.
  • Systemic congestion arises from impaired right ventricular filling or reduced output, stemming from an afterload-to-adaptation imbalance.
  • This condition carries a very poor short-term prognosis and presents significant management challenges.

Purpose of the Study:

  • To review the current understanding and management strategies for acute right heart failure in chronic precapillary pulmonary hypertension.
  • To highlight the challenges in optimal management and identify key therapeutic areas.

Main Methods:

  • Literature review focusing on the pathophysiology, prognosis, and management of ARHF in PH.
  • Analysis of current therapeutic approaches, including pharmacological support, fluid management, and advanced interventions.

Main Results:

  • Optimal management remains challenging, lacking specific recommendations.
  • Key therapeutic areas include identifying triggers, optimizing fluid volume, and pharmacological support for right ventricular function.
  • Specific management of pulmonary hypertension based on etiology is crucial for reducing right ventricular afterload.

Conclusions:

  • Extracorporeal life support and urgent transplantation have improved survival in selected refractory ARHF patients.
  • There is a significant unmet need for further research in the optimal management of this critical condition.